DBI and cancer: Although ACBP/DBI is upregulated at the transcriptional level in multiple different human cancer types (Fig. 1A), this ACBP/DBI mRNA expression only correlates with poor overall survival in a selected fraction of cancer types, including HCC, several kidney cancer subtypes, and two rather rare tumor entities, namely, adrenocortical carcinoma, low grade glioma and mesothelioma) (Fig. 1B).